Transcept wins first US middle-of-the-night sleep aid OK
This article was originally published in Scrip
Executive Summary
After twice failing to gain the US FDA's blessing to market its middle-of-the-night sleep aid, Transcept Pharmaceuticals gained that OK on 23 November for Intermezzo (zolpidem tartrate sublingual tablet) – awakening investors' interests, with shares rising as high as 37%.